Midday announcement: GLORIA PHARMA plans to sign an agreement to resolve the debt dispute related to the equity transfer of GLORIA BIO

① GLORIA PHARMA: The company plans to resolve the debt dispute regarding the equity transfer payment of Guangzhou Yuheng Biotechnology Co., Ltd. with Qingdao Pusheng Puli Enterprise Management Center by signing an agreement. Due to Pusheng Puli's failure to pay the equity transfer payment of 117.6 million yuan for the purchase of 42.12% equity in Yuheng Biotechnology within the agreed timeframe, the company filed a lawsuit in April 2024. As of now, the lawsuit has entered the enforcement stage, and the company has not received the relevant payment. Pusheng Puli intends to transfer its 20.64% equity in Yuheng Biotechnology to Youpeng Biotechnology Co., Ltd. and use the related funds to repay its debt to the company. The company, Pusheng Puli, Youpeng Biotechnology, and Yuheng Biotechnology plan to jointly sign an agreement, stipulating that Pusheng Puli will transfer 20.64% equity in Yuheng Biotechnology to Youpeng Biotechnology, and Pusheng Puli will use the proceeds to repay the debt related to the equity transfer dispute.

② New Times: November 4th is the last conversion day for "New Times Convertible Bonds." Before the market closes on that day, investors holding "New Times Convertible Bonds" can still convert their bonds. After the market closes on November 4th, "New Times Convertible Bonds" that have not been converted will stop conversion, and the remaining "New Times Convertible Bonds" will be forcibly redeemed at a price of 100.36 yuan per bond. If forcibly redeemed, investors may face losses